Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
作者信息
Winthrop K L
机构信息
Good Samaritan Hospital Clinic, 1200 NW 23rd Avenue, Portland, Oregon 97210, USA.
出版信息
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv29-30. doi: 10.1136/ard.2005.042390.
Abstract
摘要
相似文献
1
Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.肿瘤坏死因子α阻断药物相关的结核病及其他机会性感染的最新情况
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv29-30. doi: 10.1136/ard.2005.042390.
2
Late onset tuberculosis infection in patients receiving anti-TNFα therapy.接受抗TNFα治疗患者的迟发性结核感染
QJM. 2014 Jan;107(1):69-71. doi: 10.1093/qjmed/hct174. Epub 2013 Aug 22.
3
Opportunistic Infections in Biological Therapy, Risk and Prevention.生物治疗中的机会性感染、风险与预防
Rheum Dis Clin North Am. 2017 Feb;43(1):27-41. doi: 10.1016/j.rdc.2016.09.005. Epub 2016 Oct 22.
4
British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.英国胸科学会（BTS）关于对即将开始抗TNF-α治疗的患者进行结核病风险评估及管理的建议。
Rheumatology (Oxford). 2005 Oct;44(10):1205-6. doi: 10.1093/rheumatology/kei103.
5
Preventing and treating biologic-associated opportunistic infections.预防和治疗生物制剂相关的机会性感染。
Nat Rev Rheumatol. 2009 Jul;5(7):405-10. doi: 10.1038/nrrheum.2009.105.
6
Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.台湾地区肿瘤坏死因子-α抑制剂治疗类风湿关节炎患者的结核病发病风险。
Int J Tuberc Lung Dis. 2013 Dec;17(12):1590-5. doi: 10.5588/ijtld.13.0368.
7
Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.台湾类风湿性关节炎患者使用病情改善抗风湿生物制剂引发结核病、严重感染及淋巴瘤的风险
Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19. doi: 10.1111/1756-185X.12539.
8
Infections and anti-tumor necrosis factor alpha therapy.感染与抗肿瘤坏死因子α治疗
Arthritis Rheum. 2003 Nov;48(11):3013-22. doi: 10.1002/art.11301.
9
Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.与抗TNFα生物制剂在风湿性疾病治疗中停用相关的因素：来自香港生物制剂注册处的数据。
Int J Rheum Dis. 2014 Dec;17 Suppl 3:1-8. doi: 10.1111/1756-185X.12264. Epub 2013 Dec 30.
10
The yin and yang of tumor necrosis factor inhibitors.肿瘤坏死因子抑制剂的阴阳特性
Cleve Clin J Med. 2006 Mar;73(3):251-6. doi: 10.3949/ccjm.73.3.251.
引用本文的文献
1
Osteoarticular Mycoses.骨与关节真菌病。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0008619. doi: 10.1128/cmr.00086-19. Epub 2022 Nov 30.
2
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.银屑病的新型治疗方法与传染病风险
Biomedicines. 2022 Jan 21;10(2):228. doi: 10.3390/biomedicines10020228.
3
Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities.改善类风湿关节炎及相关合并症患者的护理质量的考虑因素。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001211.
4
SLE and Tuberculosis: A Case Series and Review of Literature.系统性红斑狼疮与结核病：病例系列及文献综述
J Clin Diagn Res. 2017 Feb;11(2):OR01-OR03. doi: 10.7860/JCDR/2017/22749.9398. Epub 2017 Feb 1.
5
IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study.IFNG +874T/A、IL10 -1082G/A和TNF -308G/A基因多态性与结核病易感性的关联：一项荟萃分析研究
Hum Genet. 2008 Jun;123(5):477-84. doi: 10.1007/s00439-008-0497-5. Epub 2008 Apr 15.
6
[Centrofacial granulomatous inflammation].[面部中央肉芽肿性炎症]
Hautarzt. 2007 Nov;58(11):976-8. doi: 10.1007/s00105-007-1298-9.
7
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.对于对柳氮磺胺吡啶反应欠佳的类风湿关节炎患者，柳氮磺胺吡啶与甲氨蝶呤联合治疗比单用任一药物更有效：双盲安慰剂对照MASCOT研究的结果
Ann Rheum Dis. 2007 Feb;66(2):235-41. doi: 10.1136/ard.2006.057133. Epub 2006 Aug 22.
本文引用的文献
1
Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.γ干扰素检测在结核病免疫诊断中的应用：一项系统评价
Lancet Infect Dis. 2004 Dec;4(12):761-76. doi: 10.1016/S1473-3099(04)01206-X.
2
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.使用肿瘤坏死因子抑制剂依那西普后发生的结核病。
Clin Infect Dis. 2004 Aug 1;39(3):295-9. doi: 10.1086/421494. Epub 2004 Jul 16.
3
Granulomatous infectious diseases associated with tumor necrosis factor antagonists.与肿瘤坏死因子拮抗剂相关的肉芽肿性感染性疾病。
Clin Infect Dis. 2004 May 1;38(9):1261-5. doi: 10.1086/383317. Epub 2004 Apr 15.
4
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.肿瘤坏死因子拮抗剂在HIV-1相关结核病中的安全性、免疫学、病毒学及微生物学研究。
AIDS. 2004 Jan 23;18(2):257-64. doi: 10.1097/00002030-200401230-00015.
5
Infections and anti-tumor necrosis factor alpha therapy.感染与抗肿瘤坏死因子α治疗
Arthritis Rheum. 2003 Nov;48(11):3013-22. doi: 10.1002/art.11301.
6
Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection.潜伏性结核病：宿主与杆菌导致持续感染的机制
Lancet Infect Dis. 2003 Sep;3(9):578-90. doi: 10.1016/s1473-3099(03)00741-2.
7
TNF-alpha blockade and tuberculosis: better look before you leap.肿瘤坏死因子-α阻断与结核病：行动之前最好先审视一番。
Neth J Med. 2003 Apr;61(4):111-9.
8
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.抗肿瘤坏死因子药物与结核病风险：作用机制及临床管理
Lancet Infect Dis. 2003 Mar;3(3):148-55. doi: 10.1016/s1473-3099(03)00545-0.
9
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.与英夫利昔单抗（一种肿瘤坏死因子α中和剂）相关的结核病。
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
10
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.异烟肼预防性治疗相关的肝毒性：来自一家公共卫生结核病诊所的7年调查
JAMA. 1999 Mar 17;281(11):1014-8. doi: 10.1001/jama.281.11.1014.
Zotero 插件